Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® Plus LENVIMA® In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer Life Science Investing
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Life Science Investing
Silo Wellness Submits Annual Filings After Completion of Audited Financials; Management Commentary Psychedelics Investing
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation Pharmaceutical Investing
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial Pharmaceutical Investing
